March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
40 citations
,
April 2014 in “Genes & Development” Hormones during pregnancy and lactation keep skin stem cells inactive, preventing hair growth.
27 citations
,
January 2020 in “Experimental Dermatology” Immune cells affect hair growth and could lead to new hair loss treatments.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
23 citations
,
October 2018 in “Expert Opinion on Drug Safety” Consider benefits and risks of new alopecia treatments for safety.
20 citations
,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations
,
May 2023 in “Inflammation Research” New small molecule drugs show promise in treating complex skin diseases but need more safety research.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
8 citations
,
November 2024 in “EMBO Molecular Medicine” Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
4 citations
,
July 2025 in “Frontiers in Immunology” Early intervention with JAK inhibitors may prevent alopecia areata progression.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
3 citations
,
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Curcumin applied to the skin can start hair growth in mice.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
2 citations
,
May 2017 in “InTech eBooks” Stem cells could improve hair growth and new treatments for baldness are being researched.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
October 2018 in “InTech eBooks” Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.